The JAK2V617F mutation is associated with distinct myeloproliferative neoplasms, including polycythemia vera (PV) and essential thrombocythemia (ET), but it remains unclear how it generates disparate disorders. By comparing clonally-derived mutant and wild-type cells from individual patients, we demonstrate that the transcriptional consequences of JAK2V617F are subtle, and that JAK2V617F-heterozygous erythroid cells from ET and PV patients exhibit differential interferon signaling and STAT1 phosphorylation. Increased STAT1 activity in normal CD34-positive progenitors produces an ET-like phenotype, whereas downregulation of STAT1 activity in JAK2V617F-heterozygous ET progenitors produces a PV-like phenotype. Our results illustrate the power of clonal analysis, indicate that the consequences of JAK2V617F reflect a balance between STAT5 and STAT1 activation and are relevant for other neoplasms associated with signaling pathway mutations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996868 | PMC |
| http://dx.doi.org/10.1016/j.ccr.2010.10.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms.
Ann Hematol
December 2022
Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Pauwelsstraße 30, 52074, Aachen, Germany.
Molecular diagnostics moves more into focus as technology advances. In patients with myeloproliferative neoplasms (MPN), identification and monitoring of the driver mutations have become an integral part of diagnosis and monitoring of the disease. In some patients, none of the known driver mutations (JAK2V617F, CALR, MPL) is found, and they are termed "triple negative" (TN).
View Article and Find Full Text PDFEssential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.
Ann Hematol
December 2022
Laboratory of Genomics, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.
It has been postulated that the changes in the molecular characteristics of the malignant clone(s) and the abnormal activation of JAK-STAT signaling are responsible for myeloproliferative neoplasm progression to more advanced disease phases and the immune escape of the malignant clone. The continuous JAK-STAT pathway activation leads to enhanced activity of the promoter of CD274 coding programmed death-1 receptor ligand (PD-L1), increased PD-L1 level, and the immune escape of MPN cells. The aim of study was to evaluate the PDL1 mRNA and JAK2 mRNA level in molecularly defined essential thrombocythaemia (ET) patients (pts) during disease progression to post-ET- myelofibrosis (post-ET-MF).
View Article and Find Full Text PDFAssociation of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia.
Clin Pharmacol Ther
April 2022
Department of Safety and Bioethics Section of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Article Synopsis
- - Essential thrombocythemia (ET) is a blood disorder that leads to an increase in platelet production and can cause complications like blood clots; standard low-dose aspirin does not adequately inhibit platelet function in these patients.
- - The ARES trial investigated the effectiveness of varying doses of aspirin and found that the platelet count and cytoreductive treatment (which lowers platelet levels) significantly influence how well aspirin works in ET patients, with notable differences between those on and off cytoreductive drugs.
- - Ultimately, more frequent dosing of aspirin (twice or three times daily) improves platelet inhibition and minimizes response variability among patients, regardless of whether they are undergoing cytoreductive treatment or not.
Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.
Blood
January 2021
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Interferon-α (IFN-α)-based treatments can induce hematologic and molecular responses (HRs and MRs, respectively) in polycythemia vera (PV); however, patients do not respond equally. Germline genetic factors have been implicated in differential drug responses. We addressed the effect of common germline polymorphisms on HR and MR after treatment of PV in the PROUD-PV and CONTINUATION-PV studies in a total of 122 patients who received ropeginterferon alfa-2b.
View Article and Find Full Text PDFMyeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Hematology
December 2020
Department of Medicine, The University of Hong Kong, Hong Kong, People's Republic of China.
Real-world data of responses, quality-of-life (QOL) changes and adverse events in patients with myeloproliferative neoplasms (MPN) on conventional therapy (hydroxyurea ± anagrelide), pegylated interferon alpha-2A (PEG-IFNα-2A) or ruxolitinib are limited. We prospectively studied MPN patients receiving conventional therapy, PEG-IFNα-2A or ruxolitinib. Next-generation sequencing of 69 myeloid-related genes was performed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!